DrugBank 5.0: a major update to the DrugBank database for 2018
By David S. Wishart, Y. D. Feunang, Anchi Guo, Elvis J. Lo, A. Marcu, Jason R. Grant, Tanvir Sajed, Daniel Johnson, Carin Li, Zinat Sayeeda and 12 more. Nucleic Acids Res., 2017
7,372 citations recorded by the source corpus.
Abstract DrugBank (www.drugbank.ca) is a web-enabled database containing comprehensive molecular information about drugs, their mechanisms, their interactions and their targets. First described in 2006, DrugBank has continued to evolve over the past 12 years in response to marked improvements to web standards and changing needs for drug research and development. This year’s update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years. In many cases, existing data content has grown by 100% or more over the last update. For instance, the total number of investigational drugs in the database has grown by almost 300%, the number of drug-drug interactions has grown by nearly 600% and the number of SNP-associated drug effects has grown more than 3000%. Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions. A great deal of brand new data have also been added to DrugBank 5.0. This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoprotoemics). New data have also been added on the status of hundreds of new drug clinical trials and existing drug repurposing trials. Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacological research, pharmaceutical science and drug education.
Subfields: Computational Theory and Mathematics, Molecular Biology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/98128fd412ebfa90201a276f2c59020ccc696a75
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Computational Theory and Mathematics
- Evan E. Bolton
- Sunghwan Kim
- Stephen H. Bryant
- Marinka Zitnik
- Bo Yu
- Tianfan Fu
- Jimeng Sun
- Jure Leskovec
In Molecular Biology
- David S. Wishart
- Jianguo Xia
- Jure Leskovec
- Marinka Zitnik
- Sunghwan Kim
- Evan E. Bolton
- Percy Liang
- Kexin Huang
In Pharmacology
- Sunghwan Kim
- Evan E. Bolton
- Jimeng Sun
- Tianfan Fu
- Wenhao Gao
- Marinka Zitnik
- Kexin Huang
- Connor W. Coley
Citations in the corpus
- Molecular Docking: Shifting Paradigms in Drug Discovery (2019, methodology): “For example, Luo et al. [138] performed an extensive study on more than 1200 compounds extracted from DrugBank against 600 human proteins for predicting or rationalizing drug adverse effects.”
- Network medicine framework for identifying drug-repurposing opportunities for COVID-19 (2020, methodology): “…tests the hypothesis that removing the protein targets involved in drug delivery and drug metabolism, shared by multiple drugs, can improve the specificity of the proximity measure; and P3 (Dataset S4) tests if drug-induced differentially expressed genes can offer additional predictive power (27).”
- A deep proteome and transcriptome abundance atlas of 29 healthy human tissues (2018, methodology): “Drug target genes (n=784) were obtained from Drugbank (Wishart et al. 2018) and restricted to proteins directly related to the mechanism of action for at least one of the associated drugs.”
- GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources (2022, methodology): “The information on endogenous ligands and target FDA approval status have been derived from Guide to Pharmacology (15) and DrugBank (34) databases, respectively.”
- ETCM: an encyclopaedia of traditional Chinese medicine (2018, background): “The therapeutic targets in the DrugBank database (17) of known drugs are considered as the candidate targets of the herbal ingredients with Tanimoto Scores >0.”
- FerrDb V2: update of the manually curated database of ferroptosis regulators and ferroptosis-disease associations (2022, methodology): “Drug information is retrieved on request from the DrugBank database via UniProt’s REST API (43).”
- BioTransformer: a comprehensive computational tool for small molecule metabolism prediction and metabolite identification (2019, methodology): “Potential applications might include the in silico expansion of chemical databases of drugs (e.g. DrugBank [38]), food compounds (e.g. FooDB [39]), phytochemicals (e.g. PhytoHub [40]), environmental contaminants (e.g. ContaminantDB [41], T3DB [42], the CompTox Database [43]), organism-specific…”
- Mapping the Landscape of Artificial Intelligence Applications against COVID-19 (2020, methodology): “Using a consensus between these CNN models, the authors identify a list of 15 promising drug candidates from the DrugBank dataset (Wishart et al., 2018).”
- Artificial intelligence in cancer target identification and drug discovery (2022, background): “…drug damages an entire organism, an organism ’ s substructure, or an organ. targets 34,54,57,74,80 , the principles and theory of commonly used arti fi cial intelligence biology analysis algorithms 83 – 91 , and the arti fi cial intelligence for arti fi cial intelligence biology analysis 42,195,213 .”